Guangzhou Kingmed Diagnostics Group Co., Ltd. (SHA:603882)
28.40
+0.91 (3.31%)
Nov 2, 2026, 1:25 PM CST
SHA:603882 Revenue
Guangzhou Kingmed Diagnostics Group had revenue of 1.52B CNY in the quarter ending September 30, 2026, a decrease of -1.48%. This brings the company's total for the last twelve months to 5.89B, down -3.50% year-over-year. In the year 2025, Guangzhou Kingmed Diagnostics Group had annual revenue of 6.03B, down -16.12%. That makes Guangzhou Kingmed Diagnostics Group the 8,202nd largest company in the world by revenue and 1,249th in China.
Revenue (ttm)
5.89B
Revenue Growth
-3.50%
P/S Ratio
2.13
Revenue / Employee
618.63K
Employees
9,529
Market Cap
12.97B
Revenue by Geography
- South China Area 1.69B 28.0%
- Southwest China 1.14B 18.9%
- East China Area 839.42M 13.9%
- North China Area 769.48M 12.8%
- Central China 704.30M 11.7%
- Central South Area 569.21M 9.4%
- Northeast China 316.53M 5.2%
Fiscal year ended Dec 31, 2025 See the full SHA:603882 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.03B | -1.16B | -16.12% |
| Dec 31, 2024 | 7.19B | -1.35B | -15.81% |
| Dec 31, 2023 | 8.54B | -6.94B | -44.82% |
| Dec 31, 2022 | 15.48B | 3.53B | 29.58% |
| Dec 31, 2021 | 11.94B | 3.70B | 44.88% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Dian Diagnostics Group | 9.94B |
| Hangzhou Tigermed Consulting | 7.60B |
| Shanghai Runda Medical Technology | 6.52B |
| BGI Genomics | 3.72B |
| Maccura Biotechnology Co.Ltd | 2.18B |
| Joinn Laboratories(China)Co.,Ltd. | 1.86B |
| Beijing Strong Biotechnologies,Inc. | 1.37B |
| Shanghai Labway Clinical Laboratory | 1.28B |